At 9:45 a.m. Eastern Time today, September 13, Isis will conduct a live webcast conference call to discuss this transaction. Interested parties may access the webcast at http://www.isispharm.com or listen to the call by dialing 800-289-0544. A replay will be available for a limited time at the same address.
About Isis Pharmaceuticals, Inc.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.
This press release includes forward-looking statements regarding Isis'
collaboration with Ortho-McNeil, Inc. and its affiliates, and discovery and
development of drugs for diabetes and metabolic diseases, including ISIS
325568, ISIS 377131, and drugs against undisclosed additional research
targets. Any statement describing Isis' goals, expectations, financial or
other projections, intentions or beliefs is a forward-looking statement and
should be considered an at-risk statement, including those statements that
are described as Isis' goals. Such statements are subject to certain risks
and uncertainties, particularly those inherent in the process of
discovering, developing and c
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved